9 Meters Biopharma Operating Income

As of the most recent data (March 2023), NMTR shows a operating income of $-43M. That compares with $-43M in the prior-year period — down 1.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NMTR's operating income is now $-43M (was $-43M) — a 1.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether 9 Meters Biopharma is outperforming or lagging.

Tracking NMTR's operating income over time shows whether 9 Meters Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $-43M That compares with $-43M in the prior-year period — down 1.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has 9 Meters Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-43M) with ownership activity and broader fundamentals.

9 Meters Biopharma's operating income is $-43M; compare it with other Technology names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.